Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.

Isaacson SH, Boroojerdi B, Waln O, McGraw M, Kreitzman DL, Klos K, Revilla FJ, Heldman D, Phillips M, Terricabras D, Markowitz M, Woltering F, Carson S, Truong D.

Parkinsonism Relat Disord. 2019 Jul;64:132-137. doi: 10.1016/j.parkreldis.2019.01.025. Epub 2019 Jan 28.

PMID:
30948242
2.

Changes in Nonmotor Symptoms Following an 8-Week Yoga Intervention for People with Parkinson's Disease.

Walter AA, Adams EV, Van Puymbroeck M, Crowe BM, Urrea-Mendoza E, Hawkins BL, Sharp J, Woschkolup K, Revilla FJ, Schmid AA.

Int J Yoga Therap. 2019 Mar 22. doi: 10.17761/2019-00025. [Epub ahead of print]

PMID:
30901529
3.

Conservative treatment of upper urinary tract carcinoma: Long-term results.

Andrada AO, García IL, Fúnez FA, Canet FD, Ruiz GD, Dos Santos VG, Revilla FJB.

Can Urol Assoc J. 2017 Jul;11(7):E291-E296. doi: 10.5489/cuaj.4173. Epub 2017 Jul 11.

4.

Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Mata IF, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Espay AJ, Revilla FJ, Devoto J, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Neurobiol Aging. 2017 Aug;56:211.e1-211.e7. doi: 10.1016/j.neurobiolaging.2017.04.009. Epub 2017 Apr 20.

5.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

6.

Computer-Guided Deep Brain Stimulation Programming for Parkinson's Disease.

Heldman DA, Pulliam CL, Urrea Mendoza E, Gartner M, Giuffrida JP, Montgomery EB Jr, Espay AJ, Revilla FJ.

Neuromodulation. 2016 Feb;19(2):127-32. doi: 10.1111/ner.12372. Epub 2015 Dec 1.

7.

The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease.

Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP.

Mol Neurodegener. 2015 Sep 24;10:50. doi: 10.1186/s13024-015-0045-4.

8.

Stiff-arm syndrome.

Urrea-Mendoza E, Kanter D, Revilla FJ, Dornoff E, Espay AJ.

Neurology. 2015 Sep 22;85(12):1088-9. doi: 10.1212/WNL.0000000000001962. No abstract available.

9.

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Mov Disord. 2016 Jan;31(1):95-102. doi: 10.1002/mds.26359. Epub 2015 Aug 21.

10.

Diagnostic performance of the "Huffing and Puffing" sign in psychogenic (functional) movement disorders.

Laub HN, Dwivedi AK, Revilla FJ, Duker AP, Pecina-Jacob C, Espay AJ.

Mov Disord Clin Pract. 2015 Mar 1;2(1):29-32.

11.

Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease.

Kelly VE, Johnson CO, McGough EL, Shumway-Cook A, Horak FB, Chung KA, Espay AJ, Revilla FJ, Devoto J, Wood-Siverio C, Factor SA, Cholerton B, Edwards KL, Peterson AL, Quinn JF, Montine TJ, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 Jul;21(7):692-7. doi: 10.1016/j.parkreldis.2015.04.002. Epub 2015 Apr 14.

12.

Cognitive profile of LRRK2-related Parkinson's disease.

Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP.

Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.

13.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

14.

Evaluation of mild cognitive impairment subtypes in Parkinson's disease.

Cholerton BA, Zabetian CP, Wan JY, Montine TJ, Quinn JF, Mata IF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Leverenz JB, Edwards KL.

Mov Disord. 2014 May;29(6):756-64. doi: 10.1002/mds.25875. Epub 2014 Apr 7.

15.

Spatial reorganization of putaminal dopamine D2-like receptors in cranial and hand dystonia.

Black KJ, Snyder AZ, Mink JW, Tolia VN, Revilla FJ, Moerlein SM, Perlmutter JS.

PLoS One. 2014 Feb 10;9(2):e88121. doi: 10.1371/journal.pone.0088121. eCollection 2014.

16.

Effect of dopaminergic medication on postural sway in advanced Parkinson's disease.

Revilla FJ, Larsh TR, Mani A, Duker AP, Cox C, Succop P, Gartner M, Jarrin Tejada C, Bhattacharya A.

Front Neurol. 2013 Dec 13;4:202. doi: 10.3389/fneur.2013.00202. eCollection 2013.

17.

Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.

Cholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Edwards KL, Montine TJ, Leverenz JB.

J Parkinsons Dis. 2013;3(2):205-14. doi: 10.3233/JPD-130189.

18.

Cerebral blood flow responses to dorsal and ventral STN DBS correlate with gait and balance responses in Parkinson's disease.

Hill KK, Campbell MC, McNeely ME, Karimi M, Ushe M, Tabbal SD, Hershey T, Flores HP, Hartlein JM, Lugar HM, Revilla FJ, Videen TO, Earhart GM, Perlmutter JS.

Exp Neurol. 2013 Mar;241:105-12. doi: 10.1016/j.expneurol.2012.12.003. Epub 2012 Dec 19.

19.

Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.

Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, Revilla FJ, Collier TJ; Parkinson Study Group Genetics Epidemiology Working Group.

Mov Disord. 2012 Jun;27(7):880-7. doi: 10.1002/mds.24978. Epub 2012 May 3.

PMID:
22555881
20.

Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial.

Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, Alterman R, Jankovic J, Simpson R, Junn F, Verhagen L, Arle JE, Ford B, Goodman RR, Stewart RM, Horn S, Baltuch GH, Kopell BH, Marshall F, Peichel D, Pahwa R, Lyons KE, Tröster AI, Vitek JL, Tagliati M; SJM DBS Study Group.

Lancet Neurol. 2012 Feb;11(2):140-9. doi: 10.1016/S1474-4422(11)70308-8. Epub 2012 Jan 11. Erratum in: Lancet Neurol. 2012 Mar;11(3):208.

PMID:
22239915
21.

Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease.

Espay AJ, Giuffrida JP, Chen R, Payne M, Mazzella F, Dunn E, Vaughan JE, Duker AP, Sahay A, Kim SJ, Revilla FJ, Heldman DA.

Mov Disord. 2011 Dec;26(14):2504-8. doi: 10.1002/mds.23893. Epub 2011 Sep 23.

22.

The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures.

Heldman DA, Giuffrida JP, Chen R, Payne M, Mazzella F, Duker AP, Sahay A, Kim SJ, Revilla FJ, Espay AJ.

Mov Disord. 2011 Aug 15;26(10):1859-63. doi: 10.1002/mds.23740. Epub 2011 Apr 29.

23.

Effects of deep brain stimulation of dorsal versus ventral subthalamic nucleus regions on gait and balance in Parkinson's disease.

McNeely ME, Hershey T, Campbell MC, Tabbal SD, Karimi M, Hartlein JM, Lugar HM, Revilla FJ, Perlmutter JS, Earhart GM.

J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1250-5. doi: 10.1136/jnnp.2010.232900. Epub 2011 Apr 8.

24.

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

Espay AJ, Dwivedi AK, Payne M, Gaines L, Vaughan JE, Maddux BN, Slevin JT, Gartner M, Sahay A, Revilla FJ, Duker AP, Shukla R.

Neurology. 2011 Apr 5;76(14):1256-62. doi: 10.1212/WNL.0b013e3182143537.

25.

Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.

Espay AJ, Vaughan JE, Shukla R, Gartner M, Sahay A, Revilla FJ, Duker AP.

Mov Disord. 2011 Apr;26(5):913-4. doi: 10.1002/mds.23522. Epub 2011 Mar 22. No abstract available.

PMID:
21432906
26.

At-home training with closed-loop augmented-reality cueing device for improving gait in patients with Parkinson disease.

Espay AJ, Baram Y, Dwivedi AK, Shukla R, Gartner M, Gaines L, Duker AP, Revilla FJ.

J Rehabil Res Dev. 2010;47(6):573-81.

27.

Juvenile levodopa-responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment.

Espay AJ, Paviour DC, O'Sullivan JD, Schmidt RE, Revilla FJ, Metman LV.

Mov Disord. 2010 Sep 15;25(12):1860-7. doi: 10.1002/mds.23194.

PMID:
20669183
28.

Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation.

Timmermann L, Pauls KA, Wieland K, Jech R, Kurlemann G, Sharma N, Gill SS, Haenggeli CA, Hayflick SJ, Hogarth P, Leenders KL, Limousin P, Malanga CJ, Moro E, Ostrem JL, Revilla FJ, Santens P, Schnitzler A, Tisch S, Valldeoriola F, Vesper J, Volkmann J, Woitalla D, Peker S.

Brain. 2010 Mar;133(Pt 3):701-12. doi: 10.1093/brain/awq022. Epub 2010 Mar 5.

29.

Retroperitoneal leiomyomata as a cause of bilateral hydronephrosis and lumbosciatic pain.

Rodríguez GF, Vasco PG, Callejas ME, Revilla FJ.

BMJ Case Rep. 2009;2009. pii: bcr05.2009.1857. doi: 10.1136/bcr.05.2009.1857. Epub 2009 Dec 9.

30.

Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observations.

Espay AJ, Duker AP, Chen R, Okun MS, Barrett ET, Devoto J, Zeilman P, Gartner M, Burton N, Miranda HA, Mandybur GT, Zesiewicz TA, Foote KD, Revilla FJ.

Mov Disord. 2008 Dec 15;23(16):2357-62. doi: 10.1002/mds.22271.

PMID:
18759339
31.

Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease.

Karimi M, Golchin N, Tabbal SD, Hershey T, Videen TO, Wu J, Usche JW, Revilla FJ, Hartlein JM, Wernle AR, Mink JW, Perlmutter JS.

Brain. 2008 Oct;131(Pt 10):2710-9. doi: 10.1093/brain/awn179. Epub 2008 Aug 12.

32.

Unilateral subthalamic nucleus stimulation has a measurable ipsilateral effect on rigidity and bradykinesia in Parkinson disease.

Tabbal SD, Ushe M, Mink JW, Revilla FJ, Wernle AR, Hong M, Karimi M, Perlmutter JS.

Exp Neurol. 2008 May;211(1):234-42. doi: 10.1016/j.expneurol.2008.01.024. Epub 2008 Feb 14.

33.

Teaching NeuroImage: Oculomasticatory myorhythmia: pathognomonic phenomenology of Whipple disease.

Revilla FJ, de la Cruz R, Khardori N, Espay AJ.

Neurology. 2008 Feb 5;70(6):e25. doi: 10.1212/01.wnl.0000287142.16160.0f. No abstract available.

PMID:
18250283
34.

Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease.

Tabbal SD, Revilla FJ, Mink JW, Schneider-Gibson P, Wernle AR, de Erausquin GA, Perlmutter JS, Rich KM, Dowling JL.

Neurosurgery. 2007 Sep;61(3 Suppl):119-27; discussion 127-9.

PMID:
17876242
35.

Cerebellar limb tremor and inferior olivary hypertrophy.

Espay AJ, Revilla FJ.

Neurology. 2006 Oct 10;67(7):1250. No abstract available.

PMID:
17030760
36.

Surgical treatment of movement disorders.

Espay AJ, Mandybur GT, Revilla FJ.

Clin Geriatr Med. 2006 Nov;22(4):813-25, vi. Review.

PMID:
17000337
37.

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

Strong JA, Dalvi A, Revilla FJ, Sahay A, Samaha FJ, Welge JA, Gong J, Gartner M, Yue X, Yu L.

Mov Disord. 2006 May;21(5):654-9.

PMID:
16435402
38.

Effect of stimulation frequency on tremor suppression in essential tremor.

Ushe M, Mink JW, Revilla FJ, Wernle A, Schneider Gibson P, McGee-Minnich L, Hong M, Rich KM, Lyons KE, Pahwa R, Perlmutter JS.

Mov Disord. 2004 Oct;19(10):1163-8.

PMID:
15390071
39.

Stimulation of STN impairs aspects of cognitive control in PD.

Hershey T, Revilla FJ, Wernle A, Gibson PS, Dowling JL, Perlmutter JS.

Neurology. 2004 Apr 13;62(7):1110-4.

PMID:
15079009
40.

Cortical and subcortical blood flow effects of subthalamic nucleus stimulation in PD.

Hershey T, Revilla FJ, Wernle AR, McGee-Minnich L, Antenor JV, Videen TO, Dowling JL, Mink JW, Perlmutter JS.

Neurology. 2003 Sep 23;61(6):816-21.

PMID:
14504327
41.

Different effects of unilateral versus bilateral subthalamic nucleus stimulation on walking and reaching in Parkinson's disease.

Bastian AJ, Kelly VE, Revilla FJ, Perlmutter JS, Mink JW.

Mov Disord. 2003 Sep;18(9):1000-7.

PMID:
14502667
42.

Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults.

Snider BJ, Moss JL, Revilla FJ, Lee CS, Wheeler VC, Macdonald ME, Choi DW.

Neuroscience. 2003;120(3):617-25.

PMID:
12895502
43.

Chorea and jaw-opening dystonia as a manifestation of NeuroBehcet's syndrome.

Revilla FJ, Racette BA, Perlmutter JS.

Mov Disord. 2000 Jul;15(4):741-4. No abstract available.

PMID:
10928591

Supplemental Content

Loading ...
Support Center